Correlation between pathological response to neoadjuvant immunotherapy and long-term survival in locally advanced rectal cancer: A real-world study

Table 4 Univariate analysis of factors affecting long-term survival in locally advanced rectal cancer patients

Variable	Coding	DFS (HR, 95%CI)	P value (DFS)	OS (HR, 95%CI)	P value (OS)
Sex	Male = 1, female = 0	1.025 (0.562-1.868)	0.941	1.125 (0.521-2.428)	0.765
Age (years)	≥ 60 = 1, < 60 = 0	1.258 (0.682-2.325)	0.458	1.321 (0.625-2.798)	0.468
ECOG performance status	1 = 1, 0 = 0	1.365 (0.752-2.478)	0.305	1.425 (0.712-2.852)	0.321
Tumor location	≤ 5 cm = 1, > 5 cm = 0	1.182 (0.652-2.145)	0.585	1.258 (0.652-2.425)	0.501
Maximum tumor diameter (cm)	> 4.5 = 1, ≤ 4.5 = 0	2.352 (1.201-4.598)	0.012	1.895 (0.952-3.772)	0.068
Preoperative imaging T stage	T4 = 1, T3 = 0	2.563 (1.382-4.751)	0.003	2.418 (1.215-4.812)	0.012
Preoperative imaging N stage	N2 = 1, N0-1 = 0	3.125 (1.682-5.798)	< 0.001	3.521 (1.852-6.698)	< 0.001
Hypertension	Yes = 1, No = 0	1.082 (0.582-2.015)	0.812	1.152 (0.568-2.335)	0.698
Diabetes mellitus	Yes = 1, No = 0	1.215 (0.625-2.368)	0.568	1.325 (0.632-2.778)	0.465
Treatment regimen	Immunotherapy monotherapy = 1, combination immunotherapy = 0	2.018 (1.082-3.765)	0.028	1.985 (1.012-3.895)	0.046
Pathological response	Non-MPR = 1, MPR/pCR = 0	4.256 (2.382-7.615)	< 0.001	4.892 (2.582-9.275)	< 0.001

ECOG: Eastern Cooperative Oncology Group; MPR: Major pathological response; pCR: Pathological complete response; DFS: Disease-free survival; HR: Hazard ratio; CI: Confidence interval; OS: Overall survival.